Stay updated on Vaccine Therapy with Pembrolizumab in Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Vaccine Therapy with Pembrolizumab in Prostate Cancer Clinical Trial page.

Latest updates to the Vaccine Therapy with Pembrolizumab in Prostate Cancer Clinical Trial page
- Check7 days agoChange DetectedAdded a government funding lapse notice banner stating the NIH Clinical Center is open and directing users to cc.nih.gov. Updated the page's revision identifier from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check14 days agoChange DetectedAdded a glossary toggle label and updated metadata to display 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. The older entries 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed and replaced with 'No FEAR Act Data'.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page.SummaryDifference0.0%

- Check50 days agoChange DetectedAdded a dedicated Locations section that lists Wisconsin as a site, aligning with core page content and helps users find where the study is conducted. The prior Wisconsin Locations label was removed and the page revision updated to v3.3.3.SummaryDifference0.2%

- Check78 days agoChange DetectedAdded notes clarifying that publications are provided voluntarily by study submitters and auto-filled from PubMed, and updated the revision to v3.3.2. The previous wording about publications and PubMed data provenance was removed.SummaryDifference0.1%

- Check85 days agoChange DetectedDeleted the government funding/operating status notice banner. The study details and other page content remain unchanged.SummaryDifference0.3%

Stay in the know with updates to Vaccine Therapy with Pembrolizumab in Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vaccine Therapy with Pembrolizumab in Prostate Cancer Clinical Trial page.